Apexigen, Inc.

Apexigen, Inc. (Nasdaq: APGN) is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibody-based therapies for cancer treatment, with a pipeline centered on oncology immunotherapy. The company entered the public markets through a SPAC merger with Brookline Capital Acquisition Corp., a blank-check vehicle sponsored by Brookline Capital Markets, which completed its IPO in 2021 and closed the business combination with Apexigen in 2022. Operating in the healthcare and biotechnology sector, APGN filed an 8-K with the SEC on August 23, 2023, disclosing a material corporate development. For full filing details, deal history, and SPAC analytics on APGN and thousands of other transactions, sign up for complete data access at SpacDesk.